Great question. Amvuttra (vutrisiran) is an RNA interference therapy that works by reducing the production of the abnormal TTR protein before it can build up and cause damage. Think of it like turning off a faucet rather than mopping up a spill.
However, Amvuttra's approval for polyneuropathy is specifically for hereditary Show Full Answer
Great question. Amvuttra (vutrisiran) is an RNA interference therapy that works by reducing the production of the abnormal TTR protein before it can build up and cause damage. Think of it like turning off a faucet rather than mopping up a spill.
However, Amvuttra's approval for polyneuropathy is specifically for hereditary ATTR amyloidosis (hATTR), not wild-type ATTR amyloidosis. In March 2025, it received additional FDA approval to treat ATTR cardiomyopathy, which does include wild-type. So for the cardiac side of wild-type, it's now an approved option — but for polyneuropathy specifically in wild-type, it's not currently FDA-approved for that use.
It's worth having a detailed conversation with your specialist about whether Amvuttra might still be considered in your specific situation. As for side effects, the good news is they are generally manageable. Common side effects include:
- Sore throat
- Joint pain
- Muscle pain and spasms
- Headaches
These are not typically considered severe, but everyone's experience can differ. It's always important to discuss your full health picture with your care team so they can weigh the benefits against any potential risks for you personally.
September 1
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
